- Home
- DIBS vs EQ Comparison
DIBS vs EQ Comparison
Compare DIBS & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DIBS | EQ |
|---|---|---|
| Founded | 2000 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 164.7M | 157.4M |
| IPO Year | 2021 | 2018 |
Fundamental Metrics
Financial Performance| Metric | DIBS | EQ |
|---|---|---|
| Price | $4.73 | $2.29 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $7.00 | ★ $8.00 |
| AVG Volume (30 Days) | 93.6K | ★ 504.6K |
| Earning Date | 05-08-2026 | 05-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 22.45 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $89,620,000.00 | $41,095,000.00 |
| Revenue This Year | $3.12 | N/A |
| Revenue Next Year | $1.72 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1.54 | N/A |
| 52 Week Low | $2.50 | $0.76 |
| 52 Week High | $6.62 | $3.54 |
Technical Indicators
Market Signals| Indicator | DIBS | EQ |
|---|---|---|
| Relative Strength Index (RSI) | 52.25 | 47.48 |
| Support Level | $4.46 | $1.97 |
| Resistance Level | $4.83 | $2.61 |
| Average True Range (ATR) | 0.33 | 0.19 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 53.92 | 59.32 |
Price Performance
Historical ComparisonAbout DIBS 1stdibs.com Inc.
1stdibs.com Inc is an online marketplace for connecting design lovers with the sellers and makers of vintage, antique, and contemporary furniture, home decor, jewelry, watches, art, and fashion. The company has a single reportable and operating segment that contains one reporting unit, which consists of the company's online marketplace that enables commerce between sellers and buyers. The company generates maximum revenue from fees from seller marketplace services and other services, including advertisements.
About EQ Equillium Inc.
Equillium Inc is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. It primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development. The Company operates through a single operating and reportable segment focused on the business of developing novel therapies to treat severe autoimmune and inflammatory disorders, with the mission to develop life-changing therapeutics for patients. The Company manages all business activities on a consolidated basis.